Vortex Energy 주식 가격. VRTX - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

0.055

매수가

0.055

매도가

0.06

거래량

12,020

0.055 일간 변동폭 0.055

0.055 52주 범위 0.85

전일 종가

0.055

개장가

0.055

최근 거래 시간

4000

0.055

마지막 거래 시간

23:30:04

평균 볼륨(3m)

126,480

재정 규모

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.005	-8.33333333333	0.06	0.065	0.055	118512	0.055	CS
4	-0.04	-42.1052631579	0.095	0.095	0.055	172432	0.06315517	CS
12	-0.085	-60.7142857143	0.14	0.145	0.055	126480	0.08652386	CS
26	-0.165	-75	0.22	0.27	0.055	86678	0.12250454	CS
52	-0.355	-86.5853658537	0.41	0.85	0.055	155684	0.37441598	CS
156	-0.045	-45	0.1	2.32	0.055	200075	0.92293791	CS
260	-0.045	-45	0.1	2.32	0.055	200075	0.92293791	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
SPFYSpacefy Inc	$ 0.015 (200.00%)	10k
XBLK.XeXeBlock Technology Corporation	$ 0.04 (100.00%)	1.5k
GOHGoldHaven Resources Corp	$ 0.14 (86.67%)	5k
BRSBRS Resources Ltd	$ 0.215 (53.57%)	1.1k
RFRRenforth Resources Inc	$ 0.015 (50.00%)	15.18k
ACRG.A.UAcreage Holdings Inc	US$ 0.015 (-88.89%)	207.6k
MYCOMydecine Innovations Group Inc	$ 0.005 (-50.00%)	6.89k
IANiAnthus Capital Holdings Inc	$ 0.005 (-50.00%)	1,000
BEEBee Vectoring Technologies International Inc	$ 0.005 (-50.00%)	10k
BAMMBody and Mind Inc	$ 0.01 (-33.33%)	25.5k
HODLSol Strategies Inc	$ 1.51 (21.77%)	2.11M
PXEP2Earn Inc	$ 0.005 (0.00%)	2.07M
BTCBluesky Digital Assets Corp	$ 0.87 (19.18%)	1.35M
PKKPeak Fintech Group Inc	$ 0.09 (-14.29%)	1.23M
PRMEPrime Drink Group Corp	$ 0.31 (8.77%)	961.13k